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Background: Genetic and environmental factors are critical elements influencing the etiology of major depression. It is
now accepted that neuroinflammatory processes play a major role in neuropsychological disorders. Neuroinflammation
results from the dysregulation of the synthesis and/or release of pro- and anti-inflammatory cytokines with central or
peripheral origin after various insults. Systemic bacterial lipopolysaccharide (LPS) challenge is commonly used to study
inflammation-induced depressive-like behaviors in rodents. In the present study, we investigated immune-to-brain
communication in mice by examining the effects of peripheral LPS injection on neuroinflammation encompassing
cytokine and chemokine production, microglia and central nervous system (CNS)-associated phagocyte activation,
immune cell infiltration and serotonergic neuronal function.
Methods: LPS was administered to C57BL/6 J mice by intraperitoneal injection; brains were collected and pro-
inflammatory cytokine mRNA and proteins were measured. To examine the relative contribution of the different
populations of brain immune cells to the occurrence of neuroinflammation after acute systemic inflammation, we
precisely characterized them by flow cytometry, studied changes in their proportions and level of activation, and
measured the amount of cytokines they released by Cytometric Bead Array™ after cell sorting and ex vivo culture.
Because of the central role that the chemokine CCL2 seems to play in our paradigm, we studied the effect of CCL2 on
the activity of serotonergic neurons of the raphe nucleus using electrophysiological recordings.
Results: We report that systemic LPS administration in mice caused a marked increase in pro-inflammatory IL-1β, IL-6,
TNFα and CCL2 (monocyte chemoattractant protein-1) mRNA and protein levels in the brain. Moreover, we found that
LPS caused microglia and CNS-associated phagocyte activation characterized by upregulation of CCR2, TLR4/CD14,
CD80 and IL-4Rα, associated with overproduction of pro-inflammatory cytokines and chemokines, especially CCL2. LPS
also induced a marked and selective increase of CCR2+ inflammatory monocytes within the brain. Finally, we showed
that CCL2 hyperpolarized serotonergic raphe neurons in mouse midbrain slices, thus probably reducing the serotonin
tone in projection areas.
Conclusion: Together, we provide a detailed characterization of the molecular and cellular players involved in the
establishment of neuroinflammation after systemic injection of LPS. This highlights the importance of the CCL2/CCR2
signaling and suggests a possible link with depressive disorders.
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Inflammation plays a central role in the pathogenesis of
several brain disorders, including depression. Depression
is a multifactorial disease with both genetic and environ-
mental factors. Beyond the recognized role of monoaminer-
gic systems including serotonin (5-HT), norephinephrine
(NE) and dopamine (DA), a link between inflammatory
processes and depression etiology has been firmly estab-
lished at both the clinical and preclinical levels [1-8]. De-
pression may be due to the central action of cytokines on
the hypothalamus-pituitary-adrenal (HPA) axis [9] and/or
to a reduced hippocampal neurogenesis [10-12]. Several
studies have reported that depressed patients commonly
display alterations in their immune system, including im-
paired cellular immunity and elevated levels of pro-
inflammatory cytokines in the plasma and cerebrospinal
fluid, mainly IL-1β, IL-6 and TNFα [13-16]. Further
evidence of the close link between inflammation and de-
pression comes from clinical observations showing that
patients receiving the pro-inflammatory cytokines IL-2
and interferon-α during cancer or hepatitis C treatments
frequently develop major depression symptoms [17-19].
Systemic injection of the endotoxin lipopolysaccharide
(LPS), a cell wall component of Gram-negative bacteria,
can generate many features of the acute phase response of
inflammation [20,21] and has therefore been used exten-
sively as a model for peripherally induced inflammation.
Systemic LPS causes an increase in pro-inflammatory
cytokine production in circulating or tissue-resident im-
mune cells such as monocytes and macrophages [22]. For
many years, the brain has been considered as an immuno-
logically privileged site; however, many developments in
neuro-immunology have challenged this concept [23]. In-
deed, in response to infection or injury, the brain exhibits
many hallmarks of inflammation such as edema, activa-
tion of brain mononuclear phagocytes (microglia and
macrophages), local invasion of circulating immune cells,
and production of cytokines (for review, see [24]). Periph-
erally produced cytokines (for example, after systemic LPS
challenge) may transfer an inflammatory signal to the
brain in several ways: activation in areas of the blood-
cerebrospinal fluid barrier such as choroid plexus, active
transport of cytokines across the blood–brain barrier
(BBB), or modulation of afferent nerves. Another possibil-
ity is the direct activation of certain brain cells by LPS, as
some of them express the LPS receptor, namely the Toll
like receptor 4 (TLR4) [25]. Moreover, migration of blood
cells within the central nervous system (CNS) may also
contribute to a brain inflammation state [26]. These per-
ipheral inflammatory signals stimulate innate immune
brain cells to endogenously express the same set of pro-
inflammatory cytokines [20,27].
Different immune cell populations contribute to CNS
neuroinflammation: CNS-resident microglia and CNS-associated mononuclear phagocytes, among which neu-
trophils, CNS-resident perivascular and meningeal macro-
phages, choroid plexus macrophages and CNS-infiltrating
monocyte-derived macrophages should be distinguished
[28]. However, until now, a clear vision of the precise role
of each of these populations in neuroinflammation pro-
cesses failed to emerge from the literature due to a lack
of homogeneity in their parameters of identification and
characterization.
Microglia have two main functions within the CNS:
maintenance of neuronal functions and immune defense
[29,30]. However, dysregulated and/or sustained activa-
tion of microglia may induce neuroinflammation and
contribute to progression of almost all brain diseases, in-
cluding depression [31-33]. Indeed, in experimental
studies it has been shown that CCL2 activates microglia
triggering the release of IL-1β and TNFα [34]. Moreover,
it has been shown that a single injection of IL-1β or TNFα
into selected regions of the brain results in sickness behav-
iors, activation of the HPA axis and inhibition of hippo-
campal neurogenesis, resulting in cognition impairment
and depressive-like behavior in animal models [9,21]. As
one of the main sources of pro-inflammmatory cytokines
in the brain and since they express TLR4, microglia could
be a direct target of systemic LPS challenge.
CNS-associated macrophages reside within the vascular
basement membrane in close proximity to blood vessels
[35,36]. They are also associated with the leptomeninges
[37] and the choroid plexus [38]. In inflammatory condi-
tions, the CNS-associated mononuclear phagocyte popu-
lation also includes CNS-infiltrating monocyte-derived
macrophages and neutrophils, which all could contribute
to the establishment and maintenance of a neuroinflam-
matory state [39].
In response to insult or injury, microglia and macro-
phages acquire diverse and complex phenotypes, allow-
ing them to participate in the cytotoxic response,
immune regulation, and injury resolution. Nomenclature
of these phenotypes can be characterized into four main
states, a “classically activated” M1 state with cytotoxic
properties, an “alternative activation” M2a state involved
in repair and regeneration, an “immunoregulatory” M2b
state, and a “deactivating phenotype” M2c state. These
phenotypes have known prototypical inducers: TLR4 ag-
onists as LPS and TNFα for the M1 state; IL-4 and IL-
13 for the M2a state; immune complexes, TLR4 agonists
and IL-1R ligands for the M2b state; and IL-10, trans-
forming growth factor-β and glucocorticoids for the
M2c state. However, most of the studies outlining these
inducers were performed on blood-derived macro-
phages, while microglia are known to differ in their re-
sponsiveness to stimuli [40].
It is known that peripherally administered LPS induces
an innate immune response characterized by a rapid
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sion of various pro-inflammatory mediators, and subse-
quent immune cell infiltration into the brain parenchyma
[41-48], which are pathological features of many cerebral
diseases such as depression. However, the precise molecu-
lar signaling molecular pathways and the contribution of
the different sub-populations of brain-associated micro-
glia/macrophages are not fully understood.
Pro-inflammatory cytokines also influence the 5-HT, NE
and DA neurotransmitter systems [49]. There are several
known mechanisms by which cytokines reduce serotoner-
gic neurotransmission. For example, pro-inflammatory
cytokines activate the tryptophan-kynurenine pathway
whereby tryptophan is shunted from the synthesis of 5-
HT to that of kynurenine [50,51]. Although this mechan-
ism is important in serotonergic system dysfunction in
depression, other possible mechanisms cannot be ruled
out and remain to be elucidated.
In the present study, we investigated how systemic in-
flammation triggered by a single intraperitoneal (i.p.) in-
jection of LPS affected brain inflammation, microglia
and CNS-associated phagocyte features, immune cell in-
filtration and cytokine production profiles. The conse-
quences of such inflammation on serotonergic neuronal
dysfunction were also investigated. Altogether, our re-
sults highlight the important role of the CCL2/CCR2
signaling pathway in neuroinflammation and bring new
insights regarding the mechanisms possibly involved
in the onset of neuroinflammation-related depressive
behaviors.
Methods
Animals and lipopolysaccharide administration
Eight-week-old female C57BL/6 J mice were purchased
from Janvier (Saint-Quentin-Fallavier France). All mice
were held in a temperature-controlled room maintained
under a 12-hour light/dark cycle and had access to food
and water ad libitum. Animals were handled in accord-
ance with good animal practice as defined by the rele-
vant national animal welfare bodies, equivalent to the
European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific Pur-
poses (ETS 123). Mouse experimentation protocols were
approved by the Nice Sophia Antipolis University animal
safety committee (CIEPAL-Azur, NCE/2011-21).
LPS from Escherichia coli 0111:B4 was purchased
from Sigma-Aldrich (Saint-Quentin-Fallavier, France) and
freshly dissolved in sterile saline prior to i.p. injection.
Mice were injected i.p. with vehicle (0.9% NaCl) or LPS
(2 mg/kg).
Isolation of immune cells from adult mouse brains
Mice were deeply anesthetized 24 hours post i.p. injec-
tion with a lethal injection of pentobarbital. Immunebrain cells were isolated from whole brain homogenates
as follows. Mice were transcardially perfused with ice-
cold PBS (pH 7.4, 1 mg/ml EDTA). Brains were collected
and roughly homogenized in PBS, resuspended in PBS
containing 3 mg/ml collagenase D (Roche Diagnostics,
Meylan, France) and incubated for 30 minutes at 37°C.
After incubation, brain homogenates were filtered in
70 μm pore size cell strainers (BD Biosciences, Le Pont
de Claix, France), centrifuged (10 minutes, 2,000 rpm),
washed and resuspended in 6 ml of 38% isotonic Percoll
(GE Healthcare, Aulnay Sous Bois, France), before
centrifugation (20 minutes, 2,000 rpm, 4°C). Myelin
and debris were discarded. Cell pellets containing
brain immune cells were collected, washed and labeled
for subsequent cell sorting and/or flow cytometry
analysis.
Brain immune cell staining, flow cytometry and cell
sorting
Staining of brain immune cell surface antigens was per-
formed as follows. In brief, Fc receptors were blocked
with 2.4G2 antibody. Cells were incubated with the ap-
propriate combination of conjugated antibodies: CD11b-
PercP-Cy5.5, CD45-APC-Cy7, Ly6C-PE-Cy7, Ly6G-pacific
blue, CD3-FITC, CD8-APC, major histocompatibility
complex class II-Alexa700, CD80-V450, CD86-eFluor605,
CD14-APC, TLR4-Alexa488, CD124/IL-4Rα-Biotin and
streptavidin-PE-Cy7 (BD Biosciences), CD4-Viogreen
(Miltenyi Biotec, Paris, France), CCR2-PE (R&D systems,
Lille, France) or isotype control antibodies for 30 minutes.
Cells were washed and resuspended in PBS containing
0.5% bovine serum albumin for analysis and cell sorting
with FACS Aria III (BD Biosciences).
Ex vivo culture of sorted brain immune cells
Microglia and CNS-associated phagocytes were isolated
from the saline- and LPS-treated brain of 8-week-old
mice as described above, and seeded at a density of 3 ×
104 cells/well in 96-well tissue culture plates (Falcon,
Greiner, Courtaboeuf, France) in Dulbecco's modified
Eagle's medium culture media (Invitrogen, Cergy Pontoise,
France) containing 10% fetal bovine serum. Cells were
cultured at 37°C with 5% CO2 and saturated humidity for
24 hours with or without stimulation with 0.5 μg/ml LPS.
Media were then collected and centrifuged at 1,200 rpm
for 10 minutes at 4°C. The supernatants were used for
Cytometric Bead Array™ (CBA; BD Biosciences) measure-
ment of cytokines and chemokines.
Cytokine measurement by cytometric bead array
Selected brain regions from saline- or LPS-injected
brains were homogenized in NP-40 containing buffer
(10 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40,
10% glycerol, 5 mM EDTA and protease inhibitor
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colleagues [52]. Supernatants from brain homogenates
or ex vivo cultured cells were harvested and the concen-
tration of secreted cytokines (TNFα, CCL2, IL-1β and
IL-6) was detected using a CBA according to the manu-
facturer’s instructions (BD Biosciences). For comparison,
data were normalized relative to the protein concentra-
tion of related brain homogenate, or alternatively to the
cell number.
Immunohistochemistry
To stain microglia/macrophages, mice were deeply anes-
thetized with pentobarbital and transcardially perfused
with PBS and then 3.2% paraformaldehyde. Brains were
postfixed in 3.2% paraformaldehyde for 24 hours and in-
cubated in 20% sucrose for an additional 24 hours. Fixed
brains were frozen using isopentane (−30°C) and sec-
tioned (20 μm) using a cryostat. Brain regions were iden-
tified by reference markers in accordance with the
stereotaxic mouse brain atlas. Sections were mounted on
slides and blocked with 5% goat serum. Sections were
washed and incubated with a rabbit anti-mouse ionized
calcium binding adaptor molecule 1 (Iba-1) antibody
(Abcam, Paris, France) overnight at 4°C. After washes,
the sections were incubated with secondary biotinylated
goat anti-mouse IgG and DAB staining was performed
according to manufacturer’s instructions (DAB peroxidase
substrate kit, Vector Laboratories, Clinisciences, Nanterre,
France).
RNA isolation and quantitative polymerase chain reaction
Total RNA from saline- or LPS-injected brain areas, or
from brain immune cells purified and sorted according
to CD11b and CD45 surface labeling were isolated using
the Trizol® RNA extraction kit (Invitrogen) according to
the manufacturer recommendations followed by a RQ1
DNAse (Promega, Charbonnières, France) treatment.
First-strand cDNA were synthesized from 2 μg of total
RNA with 200 U of SuperScript III reverse transcriptase
(SuperScriptIII, Invitrogen) in the appropriate buffer in
the presence of 25 μg/ml random primers, 0.5 mM deso-
xyribonucleotide triphosphate mix, 5 mM dithiothreitol,
40 U RNAsin (Promega). The reaction was incubated for
5 minutes at 25°C, then 50 minutes at 50°C, and then
inactivated for 15 minutes at 70°C. Quantitative PCR
was performed using the SYBRgreen method (Roche,
Boulogne-Billancourt, France) with the LightCycler 480
sequence detector system (Roche Diagnostics). Primers
were purchased from QIAGEN (QuantiTect primer assay,
QIAGEN, Courtaboeuf, France).
Brain slices for electrophysiological recordings
Female mice (12 to 27 days old) were anaesthetized with
1% halothane. Following decapitation, brains were rapidlyremoved and placed in cold phosphate/bicarbonate buff-
ered solution (PBBS, 4°C) composed of (mM): 125 NaCl,
2.5 KCl, 0.4 CaCl2, 1 MgCl2, 25 glucose, 1.25 NaH2PO4,
26 NaHCO3, pH 7.4 when bubbled with 95% O2/5% CO2.
Transversal 250 μm thick slices cut with a vibrating
microtome (Microm, Francheville, France) were then
transferred to an incubating chamber maintained at 34°C
in oxygenated PBBS. After 1 hour, slices were transferred
to another incubating chamber at room temperature filled
with PBBS containing additional CaCl2 (final concentra-
tion, 2 mM).Patch clamp technique
Mice brain slices containing the raphe nucleus were
placed under a Nomarski microscope (Zeiss, Marly Le
Roi, France) equipped with an infrared video camera
(Axiocam, Zeiss) in a recording chamber superfused at a
flow rate of 1 ml/minute with oxygenated PBBS (2 mM
CaCl2). Recordings from median and dorsal raphe nu-
cleus neurons were made at room temperature (25 ± 2°C)
using a Axopatch 200B (Axon Instruments, Union City,
USA). Patch clamp pipettes made from borosilicate glass
capillary (Hilgenberg, Malsfeld, Germany) had a resistance
of 2 to 8 MΩ when filled with the internal solution
containing (mM): 130 Kgluconate, 1 MgCl2, 0.3 CaCl2, 1
EGTA, 4 Mg2ATP, 0.4 Na3GTP, 10 HEPES (pH adjusted
to 7.3 with KOH). Neurons were first patch-clamped in
cell-attached mode to record spontaneous action potential
firing and then in the whole-cell configuration in current
clamp. Values of access resistance ranged from 12 to 20
MΩ and were not compensated. Measurements were
made 2 to 3 minutes after obtaining the whole cell to en-
sure dialysis. Cell capacitance and resistance were mea-
sured in voltage clamp using the pClamp Clampex
software (Axon Instruments, Union City, USA) by apply-
ing 5 mV voltage steps. Solutions were applied in the bath.
Current-clamp recordings were made in the IClamp mode
of the Axopatch 200B.
Voltage clamp data were digitized at 0.5 kHz using a
Digidata interface coupled to a microcomputer running
p-Clamp 9 (Axon Instruments).
All electrophysiological chemicals were from Sigma-
Aldrich.Statistical analysis
Statistical analysis was performed using Statistica soft-
ware™ and SigmaStat 2.03 (Jandel Sci, Castets, France).
Values are reported as mean ± SEM. Significant differ-
ences between two groups of data were determined
using a t test for continuous data, meeting parametric
assumptions of equal variance and normality. Otherwise,
a Mann–Whitney test was performed for nonparametric
data.
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Peripheral lipopolysaccharide administration induced
M1-type pro-inflammatory cytokine/chemokine mRNA
and protein profiles in mouse brain
In a first set of studies we determined the expression
of pro-inflammatory cytokine and chemokine genes
in three distinct brain regions (that is, hypothalamus,
hippocampus and the choroid plexus). We chose these
regions because they all are implicated, although in dif-
ferent ways, in neuroinflammatory processes. Indeed,
peripheral LPS challenge induces activation of the HPA
axis and causes central cytokine production in the CNS
that is responsible for sickness and depressive behaviors.
The central pro-inflammatory cytokines are responsible
for the reduction of hippocampal neurogenesis that has
been implicated in depression. Regarding the brain’s
choroid plexus, this complex structure is the source of
cerebrospinal fluid and it might also be a portal of entry
for immune cells to invade the CNS and initiate neuro-
inflammation and disorders arising therefrom.
Adult female mice were sacrificed 24 hours after
peripheral LPS injection and brains were collected.
Table 1 shows the relative mRNA expression of the pro-
inflammatory cytokines IL-1β, IL-6, TNFα and CCL2
chemokine in the hypothalamus, hippocampus and the
choroid plexus. As expected, LPS increased the mRNA
of all pro-inflammatory genes in the three examined
regions, to various extents. TNFα mRNA levels were
dramatically increased in all considered brain areas,
especially in the choroid plexus. IL-1β, IL-6 and CCL2
mRNA were highly elevated in the hippocampus, while
the increases in the hypothalamus and the choroid
plexus were modest (Table 1).
The protein amount was also assayed by CBA 24 hours
after injection in both the hypothalamus and hippocam-
pus from saline- and LPS-treated mice (Figure 1). LPS
induced an increase in all measured pro-inflammatory
cytokines and chemokines to a similar extent in the
hypothalamus and hippocampus. Indeed, in both brain
areas the CCL2 amount was dramatically increased by
LPS (95.69 ± 7.51 pg/mg versus 9,925.44 ± 1,411.33 pg/mg
in saline- and LPS-treated hypothalamus, respectively, P <
0.01; 33.34 ± 7.51 pg/mg versus 8,629.46 ± 545.68 pg/mgTable 1 Peripheral lipopolysaccharide administration induced
profiles in mouse brain
Gene expression (fold increase 24 hours post-intraperitoneal LPS)
IL-1β IL-6
Hypothalamus 6.40 ± 0.79** 2.18 ± 0.4
Hippocampus 23.02 ± 0.30*** 17.88 ± 1
Choroid plexus 6.93 ± 0.78** 2.29 ± 0.9
Adult 8-week-old C57BL/6 J female mice were injected intraperitoneally with saline
later and pro-inflammatory genes for IL-1β, IL-6, TNFα and CCL2 were determined b
*P < 0.05, **P < 0.01, ***P < 0.005 versus saline controls; ns, not significant, n = 4.in saline- versus LPS-treated hippocampus, respectively,
P < 0.001; Figure 1). In saline-treated brains, no or very
low levels of cytokines and chemokines were detectable
and LPS significantly increased the amounts of IL-1β, IL-6
and TNFα (for IL-1β: not detectable versus 6.90 ± 1.00 pg/
mg in saline- and LPS-treated mice hypothalamus, re-
spectively, P < 0.05; not detectable versus 8.48 ± 2.00 pg/
mg in saline- and LPS-treated mice hippocampus, re-
spectively, P <0.01, for IL-6: 14.37 ± 6.20 pg/mg versus
1,716.584 ± 326.52 pg/mg in saline- and LPS-treated mice
hypothalamus, respectively, P < 0.05; 3.21 ± 1.21 pg/mg
versus 1,784.19 ± 211.34 pg/mg in saline- versus LPS-
treated mice hippocampus, respectively, P < 0.05; and for
TNFα: not detectable versus 74.88 ± 10.85 pg/mg in
saline- and LPS-treated mice hypothalamus, respectively,
P < 0.05; not detectable versus 81.76 ± 29.14 pg/mg in
saline- versus LPS-treated mice hippocampus, respect-
ively, P < 0.01; Figure 1).
Peripheral lipopolysaccharide induced an increase in
central nervous system-associated phagocytes in mouse
brain
Distinguishing CNS-inflammatory monocytes, resident
macrophages and microglia based on differential antigen
expression is almost impossible using conventional im-
munohistochemical techniques, but it can be accom-
plished using specific surface marker labeling coupled to
a detailed flow cytometry analysis. Indeed, microglia and
other monocytes can essentially be identified based on
their CD11b and CD45 expression levels. Microglia ex-
press high levels of CD11b and low levels of CD45
(CD11b+/CD45low+) while the heterogeneous population
of CNS-associated phagocytes including brain macro-
phages express high levels of both CD11b and CD45
(CD11b+/CD45high+). In the front scatter and side scatter
(SSC) plots, different cell populations and cell debris
were identified in our brain cell suspensions. Dead cells,
debris and cell doublets were excluded, and a live single
immune cell gate was created and used for further analysis
(Figure 2A, upper panels). Three different populations
were identified in this gate: CD11b+/CD45high+ (CNS-as-
sociated phagocytes), CD11b+/CD45low+ (microglia), and
CD11b−/CD45 high+ cells (Figure 2A, middle panels).M1-type pro-inflammatory cytokine/chemokine mRNA
TNFα CCL2
2* 22.51 ± 1.09*** 1.33 ± 0.72*
.22* 77.71 ± 0.74*** 24.01 ± 1.74*
8* 1477.8 ± 1.25*** 2.29 ± 0.98 (ns)
(0.9% NaCl) or 2 mg/kg lipopolysaccharide (LPS). Brains were dissected 24 hours
y quantitative PCR from the hypothalamus, hippocampus and choroid plexus.
Figure 1 Peripheral lipopolysaccharide administration induces M1-type pro-inflammatory cytokine/chemokine protein profiles in mouse
brain. Mice were injected intraperitoneally with saline or 2 mg/kg lipopolysaccharide (LPS). Brains were removed 24 hours later, and the hypothalamus
and hippocampus were dissected and homogenized. The pro-inflammatory cytokines IL-1β, IL-6, TNFα and chemokine CCL2 were quantified by
cytometric bead array. Bars represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 versus saline control; n = 5.
Cazareth et al. Journal of Neuroinflammation 2014, 11:132 Page 6 of 15
http://www.jneuroinflammation.com/content/11/1/132In brains from LPS-treated mice, the percentage of
CD11b+/CD45high+ cells was significantly higher com-
pared to brains from saline-treated mice (25.12 ± 3.08%
in LPS-treated brain versus 12.98 ± 3.71 in saline-treated
brain, P < 0.05; Figure 2A, histograms). Notably, the ratio
of microglia/CNS-associated phagocytes is dramatically
different in these two conditions, being much lower after
LPS challenge (2.52 ± 0.94 in LPS-treated brain versus
6.52 ± 2.32 in saline-treated brain, P < 0.05; data not
shown). This may indicate a proliferation of resident
macrophages and/or a higher number of infiltrating cells
from the periphery. Our data does not show significant
proliferation of microglia upon LPS treatment (Figure 2A).
However, microglia proliferation might have been masked
by the dramatic increase of CNS-associated phagocytes in
the brain or might occur at a different time after LPS
challenge.
To further characterize which cell types migrate from
the periphery to the brain in cases of inflammation, we
performed detailed analysis of CD11b+/CD45high+ cells
by flow cytometry. Ly6C and Ly6G surface marker label-
ing allowed us to discriminate between three subpopula-
tions among immune brain CD11b+/CD45high+ cells.
Neutrophils were identified as CD11b+/CD45high+/
Ly6Cintermediate+/Ly6Ghigh+ cells and macrophages were
identified as CD11b+/CD45high+/Ly6Gneg- cells. Among
them, resident macrophages were identified as Ly6Cneg-
and inflammatory monocytes as Ly6Chigh+ cells (Figure 2B,
middle panel). SSC plots confirmed this discrimination,
since neutrophils are known to be SSChigh (Figure 2B,
upper panel). The specificity of Ly6C and Ly6G signals
was verified by labeling with isotype control antibodies
(data not shown). Our results showed that peripheral LPS
administration promoted a selective migration of inflam-
matory monocytes to the brain, 24 hours after treatment
(44.70 ± 6.80% of parent cells in LPS-treated mouse brain
versus 17.46 ± 0.91% in saline-treated brain, P < 0.05;
Figure 2B, left histogram). Resident macrophage percent-
age was not significantly affected by LPS treatment (14.5 ±
1.66% of parent cells in LPS-treated mouse brain versus13.7 ± 0.81% in saline-treated brain; Figure 2B, middle
histogram) while neutrophil relative percentage was re-
duced (56.6 ± 0.33% of parent cells in saline-treated mouse
brain versus 29.9 ± 3.73% in LPS-treated brain, P < 0.05;
Figure 2B, right histogram). These results do not exclude
the possibility of a proliferation of resident macrophages
and/or an infiltration of neutrophils but indicate that they
probably are minor events compared to the massive in-
flammatory monocyte increase and/or that they may
occur at a different time point after LPS challenge. It is
also interesting to note that a sub-population of the CNS-
associated phagocytes clearly overexpressed the CD11b
marker in brains of LPS-treated mice as compared to con-
trol brains (Figure 2A). Our results show that this overex-
pression was almost exclusively restricted to brain
neutrophils, suggesting their activation by systemic LPS
(data not shown).
The infiltration of lymphocytes within the brain after i.p.
injection of LPS was also studied. Among the CD11b−/
CD45high+ population, we compared CD3−/B220+ (B lym-
phocytes), B220−/CD3+/CD4+ expressing cells (CD4+ lym-
phocytes) and B220−/CD3+/CD8+ (CD8+ lymphocytes)
expressing cells in brains from saline-treated mice and
LPS-treated mice. No statistical differences were detected,
indicating than in our experimental conditions peripher-
ally administered LPS does not produce significant B or T
lymphocyte infiltration within the brain, 24 hours after
treatment (data not shown).
Peripheral lipopolysaccharide induced microglia/
macrophage M2b-type activation and CCR2 overexpression
on both cell types
Activation of peripheral macrophages through TLR4 by
LPS is described to promote the M1 state. The dramatic
increase of IL-1β, IL-6, TNFα and CCL2 gene expression
in the hippocampus and hypothalamus of LPS-treated
mice (Figure 1) suggested that LPS could cause a po-
larization of CNS-associated macrophages and microglia
cells towards a conventional pro-inflammatory activation
state of the M1 type. In order to further characterize the
Figure 2 Peripheral lipopolysaccharide induces increases in
inflammatory monocytes in mouse brain. Adult (8 weeks old)
C57BL/6 female mice were injected intraperitoneally with saline or
2 mg/kg lipopolysaccharide (LPS), and CD11b, CD45, Ly6C, Ly6G
expressions were determined by flow cytometry from brain cell
suspensions isolated 24 hours later. (A) Upper and middle panels
show representative bivariate dot plots of Percoll isolated brain cells
illustrating a gating strategy to exclude dead cells, debris and
aggregated cells, and to determine profiles based on CD11b+/CD45low+
for microglia, CD11b+/CD45high+ for central nervous system (CNS)-
associated phagocytes and CD11b−/CD45high+ cells. Lower panels
show histograms of average percentage of microglia (left), CNS-
associated phagocytes (right) in live single immune cells from brains of
saline- (white bars) and LPS-injected mice (black bars). (B) Upper panel
shows side scatter (SSC) plot. This shows that, among CNS-associated
phagocytes, macrophages/monocytes and neutrophils can be
distinguished according to their granulosity. Middle panels show
representative bivariate dot plots of phagocytes stained for Ly6G and
Ly6C illustrating a gating strategy to identify Ly6Cintermediate+/Ly6Ghigh+
neutrophils, Ly6C−/Ly6G− resident macrophages and Ly6Chigh+/Ly6G−
inflammatory monocytes. Lower panels show histograms of average
percentage of inflammatory monocytes (left), resident macrophages
(middle) and neutrophils (right) in CNS-associated phagocytes
population from brains of saline (white bars) and LPS mice (black bars).
Bars represent the mean ± SEM. *P < 0.05 versus saline control; ns, non
significant; n = 4. FSC, front scatter.
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injected mouse brains, we performed morphological
studies of both microglia and macrophages by immuno-
histochemistry with the Iba-1 antibody, which labels
both cell types, and specific surface marker examination
of each cell type by flow cytometry. Twenty-four hours
after LPS i.p. injection, Iba-1 immunohistochemistry re-
vealed that microglia/macrophages retracted their pro-
cesses and enlarged their cell bodies, confirming their
shift from a ‘resting’ to an ‘activated’ state (Figure 3A).
We chose to examine as M1 markers the expression of
the co-stimulatory molecules CD80 and CD86, the
major histocompatibility complex class II, the chemo-
kine receptor 2 (CCR2), the TLR4/CD14 complex, and
IL-4Rα as M2 activation markers.
In the periphery, inflammatory monocytes express
CCR2, emerge from bone marrow in response to chemo-
kines such as CCL2, and home to sites of inflammation.
In order to study whether brain CCL2 release after sys-
temic LPS challenge could also affect CCR2 expressing
cells within the brain and periphery, we examined CCR2
expression by flow cytometry on microglia and CNS-
associated phagocytes in brains from control and LPS-
injected mice. Figure 3B (left histogram) shows that
the percentage of CCR2-expressing microglia cells in-
creased with LPS treatment. In the population of inflam-
matory monocytes, CCR2 expression was higher in basal
conditions as compared to microglia (5.9 ± 1.27% of in-
flammatory monocytes versus 2.05 ± 0.31% of microglia
in brains of saline-treated mice, Figure 3B,D) and was
Figure 3 Peripheral lipopolysaccharide induces microglia/monocyte M2b-type activation and CCR2 overexpression in both cell types.
Brain sections from saline- and lipopolysaccharide (LPS)-injected mice were stained with ionized calcium binding adaptor molecule 1 (Iba-1)
antibody (A) (n = 3) or cells were prepared for flow cytometry analysis (B-E). (A) Representative pictures of Iba-1 immunoreactive cells in the
hippocampus of brains from saline (left) and LPS-injected (right) mice. (B, D) Histograms of average percentage of microglia (B) or inflammatory
monocytes (D) expressing CCR2 (left) and TLR4/CD14 complex (right) in live single immune cell suspensions from brains of saline- (white bars)
and LPS-injected mice (black bars). (C,E) Graphs and histograms of mean fluorescent intensity for CD80 (left) and CD124/IL-4Rα (right) in enriched
microglia (C) and enriched central nervous system (CNS)-associated phagocyte (E) populations from brains of saline- (white bars) and LPS-treated
mice (black bars). Bars represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005 versus saline control; n = 4.
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2.26% of parent cells in brains of LPS-i.p. mice versus
5.8 ± 1.27 in brains of saline-treated mice, P < 0.005;
Figure 3D, left histogram), suggesting an important role
of the CCL2/CCR2 signaling pathway in attraction/mi-
gration of immune cells to the brain during inflamma-
tory processes. Antibody specificity was checked using
isotype control antibody labeling on microglia and mac-
rophages (data not shown).
Figure 3B,D (right histograms) confirmed that micro-
glia and CNS-associated phagocytes expressed both
TLR4 receptor and CD14, and that LPS treatment in-
creased their expression. Figure 3C,E shows that CD80
expression level was upregulated by LPS i.p. injection in
both microglia and CNS-associated phagocytes. Con-
versely, CD86 expression was barely detectable on both
cell types and was not significantly affected by LPS treat-
ment (data not shown). In accordance with a recent
publication [53], LPS treatment induced high expression
levels of IL-4Rα on the surface of microglia (Figure 3C).
Our results provide the additional information that
CNS-associated phagocytes present in the brain after
LPS i.p. also express high levels of IL-4Rα (Figure 3E,
right panels). These results are consistent with the re-
cent publication suggesting that LPS would promote a
state of activation of the M1 type of microglia while
making them more sensitive to the M2-promoting ef-
fects of some anti-inflammatory cytokines such as IL-4
[53]. Our results on inflammatory monocytes suggest
that this cell population would acquire the same peculiar
phenotype. In contrast to previous works on rat brain
[54,55], no overexpression of major histocompatibility
complex class II on the surface of microglia cells or
CNS-associated phagocytes following treatment with
LPS was observed (data not shown), suggesting that,
24 hours after LPS i.p. administration, the antigen pres-
entation function of microglia might not be altered in
our experimental model. Moreover, no expression of the
dendritic marker CD11c was detected at the surface of
the immune brain cells (data not shown) 24 hours after
LPS i.p. injection.
Lipopolysaccharide promoted M1-type pro-inflammatory
cytokine production by microglia and central nervous
system-associated phagocytes sorted from mouse brain
To delve deeper into the understanding of LPS direct ef-
fects on microglia and CNS-associated phagocyte activa-
tion, we identified these two populations in control
mouse brain cell suspension according to CD11b and
CD45 marker expression levels as previously shown. We
separately sorted them from untreated mouse brains and
stimulated them ex vivo with LPS for 24 hours. CBA
analysis of secretion media revealed that LPS induced
dramatic increases in IL-6 and TNFα release by bothmicroglia and CNS-associated phagocyte populations
(Figure 4A). Interestingly, LPS did not elicit the same ef-
fects on IL-1β and CCL2 production in these two cell
populations. Indeed, whereas ex vivo LPS treatment in-
duced a strong increase of IL-1β production by sorted
microglia, it did not alter IL-1β release by CNS-associated
phagocytes (Figure 4A). On the contrary, LPS treatment
promoted CCL2 production by sorted phagocytes but not
by microglia (Figure 4A). These experiments allowed us to
emphasize distinct sensitivity and responsiveness of
microglia and CNS-associated phagocytes to direct ex vivo
stimulation by LPS.
It is clear that peripheral administration of LPS pro-
motes a neuroinflammatory response; however, how
peripheral LPS induces its effects on the brain is not
exactly known. In order to compare direct effects of LPS
on microglia/phagocytes with indirect effects of periph-
erally administered LPS, we sorted microglia and CNS-
associated phagocytes from mouse brains 24 hours after
saline or LPS i.p. injection, cultured them for 24 add-
itional hours without ex vivo restimulation, and analyzed
secretion of cytokines and chemokines. Microglia sorted
from the brain of LPS-treated mice retained their in-
flammatory characteristics after sorting as they secreted
significantly more IL-1β, TNFα and CCL2 than control
microglia from the brain of saline-treated mice (Figure 4B).
IL-6 release by sorted microglia was not significantly af-
fected by peripheral LPS treatment and stayed below the
detection range in both conditions (Figure 4B). Analysis of
secretion media from sorted CNS-associated phagocytes
revealed that LPS only affected CCL2 release by those
cells, while other cytokine secretions remained unchanged
or below detection range (Figure 4B). These results show
that LPS administered peripherally does not produce the
same pro-inflammatory effects on microglia and brain
phagocytes as when it is administered directly in culture.
These data suggest the existence of probable intermediates
between LPS and microglia/phagocytes in the brain and
highlight the predominant role of the CCL2 chemokine in
neuroinflammation induced by peripheral LPS challenge.
This hypothesis is further reinforced by results showing
that intracerebroventricular injection of LPS caused a
massive and selective increase of IL-6 and CCL2 levels by
sorted microglia and CNS-associated phagocytes, respect-
ively, similarly to direct ex vivo stimulation but differently
from in vivo stimulation (data not shown).
CCL2 hyperpolarized serotonergic dorsal and median
raphe neurons in mouse midbrain slices
Although a dysfunction of the serotonergic system alone
cannot explain the full pathophysiology of depression,
it is considered one of the key factors in this disease.
Here we examined whether pro-inflammatory chemo-
kine CCL2 could alter serotonergic neuronal activity in
Figure 4 Lipopolysaccharide promotes M1 pro-inflammatory cytokines and chemokine production by microglia and central nervous
system-associated phagocytes sorted from mouse brain. Microglia and central nervous system (CNS)-associated phagocyte enriched cell
populations were sorted according to CD11b and CD45 expression patterns, resuspended and incubated in culture medium for an additional
24 hours. Pro-inflammatory cytokines IL-1β, IL-6, TNFα and CCL2 chemokine were quantified by cytometric bead array. (A) Ex vivo stimulation with
0.5 μg/ml lipopolysaccharide (LPS) (black bars) compared to saline control (white bars). (B) In vivo stimulation by LPS injections in mice as described in
Methods (black bars) compared to saline injections (white bars). Bars represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005 versus saline control;
n = 3-8. i.p., intraperitoneal.
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rotonergic input to the forebrain.
In transverse acute brain slices of mesencephalon, we
recorded neurons using the patch-clamp technique at
the level of the dorsal and median raphe nucleus. Neu-
rons were first recorded in cell-attached mode, and
the firing frequency was determined when the neurons
where spontaneously active. The firing frequency ranged
from 0.2 to 4 Hz with a mean of 1.22 ± 0.35 Hz (n = 7).
When possible, we switched to whole cell in the current-
clamp mode and determined the membrane potential ofthe neurons. The membrane potential of the presumed
serotonergic neurons ranged from −60 to −40 mV
with an average of −55.00 ± 3.27 mV. Neurons were
then recorded in the current-clamp mode. They were
first characterized by their responses to current steps
of increasing amplitude (Figure 5A). Serotonergic neurons
express 5HT-1a receptors which, upon activation by
serotonin, induce the activation of a G protein-coupled
inwardly-rectifying potassium channel and subsequent
hyperpolarization [56]. The recorded neurons were further
identified as serotonergic when they were hyperpolarized
Figure 5 CCL2 hyperpolarizes serotonergic dorsal and median raphe neurons in mouse midbrain slices. (A) Example of recordings of the
membrane potential of a presumed serotonergic neuron from the raphe nucleus recorded in current-clamp in response to increasing current
pulses from −20 pA to 70 pA with an increment of 10 pA. (B) Spontaneous action potential discharge of a presumed sertonergic neuron recorded in
current clamp and its response to the application of serotonin in the bath (5-HT; as indicated by the bar). (C) Graph presenting the instantaneous
frequency of action potential discharge of a presumed serotonergic neuron recorded extracellularly in loose patch. The inset presents an example of
recording obtained. (D) Spontaneous action potential discharge of a presumed serotonergic neuron recorded in current clamp and its response to the
application of 1 nM CCL2 in the bath (as indicated by the bar).
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5-HT (5 μM), applied at the end of the recording
(Figure 5B).
In presumed serotonergic neurons, we observed that
CCL2 (1 nM) induced a decrease in the instantaneous
firing frequency of neurons recorded in extracellular
mode (Figure 5C) as well as current-clamp mode
(Figure 5D) in 6 out of 7 neurons. This decrease in firing
frequency was accompanied by a hyperpolarization ran-
ging from −2 to −30 mV (with a mean of −10.50 ±
4.06 mV, n = 6); that is of a similar magnitude to that ob-
tained following the application of 5 μM serotonin (com-
pare Figure 5B and D). The application of CCL2 induced
a decrease in the membrane resistance of the neurons
(n = 5, data not shown), suggesting that CCL2 induced
the opening of G-protein activated potassium channels
in the membrane. Overall, CCL2 decreased the firing of
5-HT neurons by hyperpolarizing them and by decreas-
ing their membrane resistance.
Discussion
Previous studies indicate that peripheral immune chal-
lenge induces depressive-like behavior in rodents and
humans (for review, see [57]). This corresponds to the
induction of neuroinflammation, characterized by over-
production of pro-inflammatory cytokines, mainly IL-1β
and TNFα, within the brain, resulting in HPA axis per-
turbations, microglia activation, peripheral immune cell
infiltration, hippocampal neurogenesis inhibition and se-
rotonergic transmission alteration (for review, see [58]),but the relative contribution of cytokines/chemokines
and brain-resident or brain-infiltrating immune cells
remained unclear.
In this study, we demonstrate that acute systemic LPS
challenge elicits a pro-inflammatory signature in differ-
ent brain areas involved in depressive processes (such as
the hypothalamus and hippocampus). Although LPS is
known to induce the synthesis and release of many pro-
inflammatory mediators, which cytokines are involved in
the LPS-induced brain mediated responses needed to be
clarified. We show that the profile of cytokines and che-
mokines produced within the brain after LPS injection
corresponds to a M1 classical type of activation of
microglia/macrophages. Interestingly, we also found a
highly significant upregulation of IL-4Rα expression, a
specific marker of the M2c “classical deactivation” state,
on the surface of both microglia and CNS-associated
monocytes. This is in agreement with publications show-
ing that the simultaneous increase of markers of both
classical activation and classical deactivation triggered by
LPS is consistent with the proposed M2b monocyte
phenotype [53,59,60]. However, unlike the results of
Fenn and colleagues [53], we did not detect any increase
in the LPS-treated brain of the anti-inflammatory cyto-
kine IL-10 (data not shown). In conclusion, we can
speculate that IL-4Rα may be upregulated on microglia
and CNS-associated monocytes in order to promote a
microglial phenotype permissive to tissue repair and the
resolution of inflammation in response to increased
levels of IL-4 [59,60].
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nisms and neurodegenerative diseases often shows gaps
or inaccuracies regarding the discrimination between
microglial cells, resident macrophages of the brain, and
monocytes infiltrating the CNS in pathological condi-
tions. In this study, we performed detailed flow cytome-
try analysis to distinguish these cell populations and
decipher their respective sensitivity and responsiveness
to a peripheral LPS challenge. With this technique, we
show that systemic LPS promotes an important increase
in inflammatory monocytes within the brain. Our results
do not exclude the possibility of a proliferation of micro-
glia and/or CNS-resident macrophages; however, this
might be a minor event as compared to the massive mi-
gration of inflammatory monocytes from the periphery,
at least 24 hours post-infection. Upregulation of the
CD45 marker on the surface of microglia has been de-
scribed. This could lead to the misidentification of
microglia and CNS-associated monocyte populations in
mice treated with LPS. However, it is unlikely that
microglia were confused with inflammatory monocytes
or neutrophils because microglia express neither Ly6G
nor Ly6C (data not show). One can then imagine that
some of the activated microglia overexpressing CD45
could be confused with CNS-associated monocytes.
However, flow cytometry analysis revealed that microglia
had a smaller size compared with monocytes and, al-
though they displayed elevated CD45 levels and in-
creased size and granularity in inflammation conditions,
they could still be distinguishable from monocytes (data
not shown and [61]).
The choroid plexus epithelium constitutes the struc-
tural basis of the blood-cerebrospinal fluid barrier. Inter-
estingly, the selective increase of TNFα mRNA that we
observe in this structure (see Table 1) may indicate alter-
ations in the choroid plexus epithelial cell barrier [62]
that could explain the infiltration of peripheral immune
cells upon LPS treatment. It is noteworthy that this
modification of choroid plexus permeability did not re-
sult in the migration of non-specific immune cells within
the brain. Indeed, no neutrophils, T or B lymphocyte
entry was observed 24 hours after LPS injection, in spite
of the increase in IL-1β that we observed, which was
previously described to induce the infiltration of leuko-
cytes and neutrophils within the brain, although in a
very different type of experimental conditions [63].
Direct LPS action on choroid plexus or BBB perme-
ability is one of the possible mechanisms that have been
proposed to explain LPS effects on the CNS. Alterna-
tively, LPS could act outside the BBB by stimulating af-
ferent nerves, acting at circumventricular organs, and
indirectly altering BBB permeability and functions. LPS
could also promote a general inflammatory response
in the periphery, leading to modified immune cell andcytokine/chemokine profiles that could have an impact
on the brain inflammatory status through microglia and
CNS-associated monocytes and immune cell infiltration.
Recent data from Banks and Erickson showed that brain
uptake of circulating LPS was negligible and that most
effects of peripherally administered LPS were likely me-
diated through LPS receptors located outside the BBB
[64]. However, this conclusion is difficult to reconcile
with our results showing a marked increase in the ex-
pression of TLR4 on microglia cells after systemic injec-
tion of LPS.
The chemokine CCL2 is known to facilitate recruit-
ment of Ly6Chigh+ inflammatory monocytes, expressing
high levels of CCR2, to lesion sites outside the CNS
[65]. Here we show that the increase of CCL2 mRNA
and protein amounts in the brain after systemic LPS is
associated with an upregulation of CCR2+ expressing
microglia and inflammatory monocytes, suggesting that
cerebral CCL2 could also be responsible for peripheral
immune cell migration into the brain in neuroinflamma-
tory conditions. Although we did not demonstrate that
these inflammatory monocytes do infiltrate brain paren-
chyma, it would be interesting to investigate whether
such migration and/or infiltration would have beneficial
or deleterious effects in the CNS [66]. The results ob-
tained in this study answer, at least partially, this ques-
tion. Indeed, the precise identification by flow cytometry
of microglia and CNS-associated phagocytes allowed us
to develop an efficient technique of selective cell sorting
of these cell populations that we maintained in culture
for 24 hours in order to analyze the cytokines and che-
mokines that they release, which are likely to reflect
what they secrete in situ. One cannot exclude the possi-
bility that the brain cell suspension protocol, cell sorting
procedure and culture conditions might have modified
microglia and monocyte features; however, this is very
unlikely as we demonstrate that microglia sorted from
control mice still have the ability to activate under the
influence of ex vivo stimulation by LPS and that signifi-
cant and coherent differences between cells sorted from
brains of saline- and LPS-treated mice still are detect-
able. Moreover, it should be noted that such techniques
are routinely used by immunologists to study inflamma-
tory features of cytokines and chemokines secreting
immune cells. Interestingly, our results highlight that
microglia and CNS-associated phagocytes should abso-
lutely be distinguished when studying neuroinflamma-
tory processes as these two cell populations do not have
the same sensitivity and responsiveness characteristics
towards in vivo or ex vivo stimulation with LPS. Indeed,
our study highlights the fact that if an in vivo treatment
with LPS elicits IL-1β, TNFα and CCL2 release by
microglia, it might only trigger CCL2 release by CNS-
associated phagocytes. This indicates that CCL2 released
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traction of circulating CCR2+ inflammatory monocytes.
These cells also secrete CCL2, thus elevating even more
the cerebral CCL2 level, possibly creating an amplifica-
tion loop that could explain the magnitude of the infil-
tration of these cells into the brain. In brain immunity,
blood monocyte-derived macrophages may have similar
functions in brain repair to the ones they have in periph-
eral injuries such as skin wounds and myocardial infarcts
[67]. Indeed, monocytes and their tissue-related macro-
phages are key regulators in tissue healing processes,
which is a phenomenon that is schematically biphasic. In
infarct, for example, Ly6Chigh pro-inflammatory CCR2+
monocytes attracted to the damaged heart by release of
CCL2 dominate on days 1 to 4 (phase 1) and promote di-
gestion of infarcted tissue and removal of necrotic debris,
whereas reparative Ly6Clow CCR2− monocytes dominate
during the resolution of inflammation (phase 2) and
propagate repair. Such mechanisms are thought to also
occur in the case of brain damage. Microglia and astro-
cytes produce CCL2 upon pro-inflammatory stimulus
(systemic LPS in the present study), responsible for re-
cruitment of blood Ly6Chigh pro-inflammatory CCR2+
monocytes within 24 hours (as shown by our results). We
did not investigate brain-associated monocyte phenotype
later on after LPS injection; however, it is likely that after
this early pro-inflammatory phase 1, a following tissue re-
pair phase 2 of active resolution of inflammation would
occur.
Our results points to CCL2/CCR2 signaling as a cru-
cial element in the development of neuroinflammation
in the first days following a peripheral infection. This is
supported by a previous study by Thompson and col-
leagues showing that CCL2−/− mice show a downregula-
tion of brain pro-inflammatory cytokine production and
decreased activation of brain immune cells after sys-
temic LPS treatment compared to wild-type CCL2+/+
mice, despite a higher level of pro-inflammatory cytokines
in the serum [68]. Additionally, Wohleb and colleagues
showed that anxiety-like behavior associated with repeated
social defeat was linked to CCR2-mediated recruitment of
peripheral monocytes into the brain [69,70].
Although complex emotional states cannot be reduced
to the imbalance of a single neurotransmitter, a promin-
ent participation of 5-HT in depression and anxiety is
generally acknowledged [71]. From our results on the
hippocampus and hypothalamus and the results from
the literature, it is likely that the increased CCL2 level in
response to systemic LPS injection is widespread in all
areas of the brain parenchyma, including the median
and dorsal raphe nucleus. We thus examined whether
CCL2 could directly regulate 5-HT release by serotoner-
gic neurons of the median and dorsal raphe nucleus.
Our results show that CCL2 induced a hyperpolarizationand a decrease in firing of serotonergic neurons of the
median and dorsal raphe nucleus. These results are in
agreement with the effects of other chemokines on sero-
tonergic neurons [72,73] and extend to 5-HT neurons
the neuromodulatory effects of CCL2 already demon-
strated in other neuronal populations such as neurons of
the dorsal root ganglion [74], dopaminergic neurons of
the substantia nigra [75] or melanin concentrating hor-
mone neurons (unpublished data of Alice Guyon). These
effects of CCL2 on 5-HT neurons should lead to a re-
duction of 5-HT release in projection areas such as the
amygdala and hippocampus, two regions implicated in
the regulation of emotional expression and memory pro-
cesses affected in major depression. However, one can
hypothesize that in our experiments CCL2 may act on
neurons through CCR2-independent pathways. This hy-
pothesis cannot be totally ruled out inasmuch it has been
recently shown that CCL2, acting on benzodiazepine sites,
can modulate the GABA-evoked currents, depending on
the subunit composition of GABA(A) receptor [76].
Conclusions
In conclusion, our data suggest that during endotoxemia
caused by acute systemic LPS challenge, CCL2 is a crucial
element for full activation of the brain resident immune
cells, production of endogenous brain inflammatory medi-
ators, inflammatory immune cell infiltration and reduction
of 5-HT release by serotonergic neurons; all of these ele-
ments being linked to the establishment of depressive
behaviors.
More generally, this study brings new elements em-
phasizing the importance of neuroimmunopsychophar-
macology aimed at studying the functional interactions
between living conditions, the central and peripheral
nervous system, the immune system and the conse-
quences of this dialogue on physical and mental health.
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